GALNT3 (GalNAc Transferase 3) is a member of the polypeptide N-acetylgalactosaminyltransferase (ppGalNAc-T) family of enzymes, which are responsible for initiating mucin-type O-glycosylation. This family comprises a group of homologous enzymes that catalyze the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of serine or threonine residues in proteins.
GALNT3, like other ppGalNAc-Ts, is a Golgi-resident enzyme. It plays a crucial role in post-translational modification of proteins by adding the initial sugar in O-linked glycan chains. This process is fundamental for the proper structure and function of numerous secreted and membrane-bound proteins, including mucins, receptors, and signaling molecules. The specificity and substrate preference vary among the different GALNT isoforms, contributing to the complexity and diversity of O-glycosylation patterns.
Dysregulation of GALNT3 expression or function has been implicated in various physiological and pathological processes. Altered O-glycosylation initiated by GALNT enzymes can affect protein stability, cellular adhesion, cell-cell communication, and immune responses. Consequently, changes in GALNT3 activity have been associated with the development and progression of certain diseases, including various types of cancer, where aberrant glycosylation is a common hallmark. Research continues to explore the precise roles of GALNT3 in health and disease, including its potential as a diagnostic marker or therapeutic target.